Hemopexin and haptoglobin: Allies against heme toxicity from hemoglobin not contenders

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

The goal here is to describe our current understanding of heme metabolism and the deleterious effects of "free" heme on immunological processes, endothelial function, systemic inflammation, and various end-organ tissues (e.g., kidney, lung, liver, etc.), with particular attention paid to the role of hemopexin (HPX). Because heme toxicity is the impetus for much of the pathology in sepsis, sickle cell disease (SCD), and other hemolytic conditions, the biological importance and clinical relevance of HPX, the predominant heme binding protein, is reinforced. A perspective on the function of HPX and haptoglobin (Hp) is presented, updating how these two proteins and their respective receptors act simultaneously to protect the body in clinical conditions that entail hemolysis and/or systemic intravascular (IVH) inflammation. Evidence from longitudinal studies in patients supports that HPX plays a Hp-independent role in genetic and non-genetic hemolytic diseases without the need for global Hp depletion. Evidence also supports that HPX has an important role in the prognosis of complex illnesses characterized predominantly by the presence of hemolysis, such as SCD, sepsis, hemolytic-uremic syndrome, and conditions involving IVH and extravascular hemolysis (EVH), such as that generated by extracorporeal circulation during cardiopulmonary bypass (CPB) and from blood transfusions. We propose that quantitating the amounts of plasma heme, HPX, Hb-Hp, heme-HPX, and heme-albumin levels in various disease states may aid in the diagnosis and treatment of the above-mentioned conditions, which is crucial to developing targeted plasma protein supplementation (i.e., "replenishment") therapies for patients with heme toxicity due to HPX depletion.

Original languageEnglish (US)
Article number187
JournalFrontiers in Physiology
Volume6
Issue numberJUN
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hemopexin
Haptoglobins
Heme
Hemoglobins
Hemolysis
Sickle Cell Anemia
Sepsis
Inflammation
Hemolytic-Uremic Syndrome
Extracorporeal Circulation
metsulfuron methyl
Cardiopulmonary Bypass
Blood Transfusion
Longitudinal Studies
Blood Proteins
Albumins
Pathology
Kidney
Lung

Keywords

  • Erythrophagocytosis
  • Haptoglobin
  • Heme
  • Hemolysis
  • Hemolytic index
  • Hemopexin
  • Iron
  • Plasma protein therapeutics

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Hemopexin and haptoglobin : Allies against heme toxicity from hemoglobin not contenders. / Smith, Ann; McCulloh, Russell J.

In: Frontiers in Physiology, Vol. 6, No. JUN, 187, 01.01.2015.

Research output: Contribution to journalReview article

@article{87200b3ede084a5e8e96f726b25d3293,
title = "Hemopexin and haptoglobin: Allies against heme toxicity from hemoglobin not contenders",
abstract = "The goal here is to describe our current understanding of heme metabolism and the deleterious effects of {"}free{"} heme on immunological processes, endothelial function, systemic inflammation, and various end-organ tissues (e.g., kidney, lung, liver, etc.), with particular attention paid to the role of hemopexin (HPX). Because heme toxicity is the impetus for much of the pathology in sepsis, sickle cell disease (SCD), and other hemolytic conditions, the biological importance and clinical relevance of HPX, the predominant heme binding protein, is reinforced. A perspective on the function of HPX and haptoglobin (Hp) is presented, updating how these two proteins and their respective receptors act simultaneously to protect the body in clinical conditions that entail hemolysis and/or systemic intravascular (IVH) inflammation. Evidence from longitudinal studies in patients supports that HPX plays a Hp-independent role in genetic and non-genetic hemolytic diseases without the need for global Hp depletion. Evidence also supports that HPX has an important role in the prognosis of complex illnesses characterized predominantly by the presence of hemolysis, such as SCD, sepsis, hemolytic-uremic syndrome, and conditions involving IVH and extravascular hemolysis (EVH), such as that generated by extracorporeal circulation during cardiopulmonary bypass (CPB) and from blood transfusions. We propose that quantitating the amounts of plasma heme, HPX, Hb-Hp, heme-HPX, and heme-albumin levels in various disease states may aid in the diagnosis and treatment of the above-mentioned conditions, which is crucial to developing targeted plasma protein supplementation (i.e., {"}replenishment{"}) therapies for patients with heme toxicity due to HPX depletion.",
keywords = "Erythrophagocytosis, Haptoglobin, Heme, Hemolysis, Hemolytic index, Hemopexin, Iron, Plasma protein therapeutics",
author = "Ann Smith and McCulloh, {Russell J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3389/fphys.2015.00187",
language = "English (US)",
volume = "6",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",
number = "JUN",

}

TY - JOUR

T1 - Hemopexin and haptoglobin

T2 - Allies against heme toxicity from hemoglobin not contenders

AU - Smith, Ann

AU - McCulloh, Russell J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The goal here is to describe our current understanding of heme metabolism and the deleterious effects of "free" heme on immunological processes, endothelial function, systemic inflammation, and various end-organ tissues (e.g., kidney, lung, liver, etc.), with particular attention paid to the role of hemopexin (HPX). Because heme toxicity is the impetus for much of the pathology in sepsis, sickle cell disease (SCD), and other hemolytic conditions, the biological importance and clinical relevance of HPX, the predominant heme binding protein, is reinforced. A perspective on the function of HPX and haptoglobin (Hp) is presented, updating how these two proteins and their respective receptors act simultaneously to protect the body in clinical conditions that entail hemolysis and/or systemic intravascular (IVH) inflammation. Evidence from longitudinal studies in patients supports that HPX plays a Hp-independent role in genetic and non-genetic hemolytic diseases without the need for global Hp depletion. Evidence also supports that HPX has an important role in the prognosis of complex illnesses characterized predominantly by the presence of hemolysis, such as SCD, sepsis, hemolytic-uremic syndrome, and conditions involving IVH and extravascular hemolysis (EVH), such as that generated by extracorporeal circulation during cardiopulmonary bypass (CPB) and from blood transfusions. We propose that quantitating the amounts of plasma heme, HPX, Hb-Hp, heme-HPX, and heme-albumin levels in various disease states may aid in the diagnosis and treatment of the above-mentioned conditions, which is crucial to developing targeted plasma protein supplementation (i.e., "replenishment") therapies for patients with heme toxicity due to HPX depletion.

AB - The goal here is to describe our current understanding of heme metabolism and the deleterious effects of "free" heme on immunological processes, endothelial function, systemic inflammation, and various end-organ tissues (e.g., kidney, lung, liver, etc.), with particular attention paid to the role of hemopexin (HPX). Because heme toxicity is the impetus for much of the pathology in sepsis, sickle cell disease (SCD), and other hemolytic conditions, the biological importance and clinical relevance of HPX, the predominant heme binding protein, is reinforced. A perspective on the function of HPX and haptoglobin (Hp) is presented, updating how these two proteins and their respective receptors act simultaneously to protect the body in clinical conditions that entail hemolysis and/or systemic intravascular (IVH) inflammation. Evidence from longitudinal studies in patients supports that HPX plays a Hp-independent role in genetic and non-genetic hemolytic diseases without the need for global Hp depletion. Evidence also supports that HPX has an important role in the prognosis of complex illnesses characterized predominantly by the presence of hemolysis, such as SCD, sepsis, hemolytic-uremic syndrome, and conditions involving IVH and extravascular hemolysis (EVH), such as that generated by extracorporeal circulation during cardiopulmonary bypass (CPB) and from blood transfusions. We propose that quantitating the amounts of plasma heme, HPX, Hb-Hp, heme-HPX, and heme-albumin levels in various disease states may aid in the diagnosis and treatment of the above-mentioned conditions, which is crucial to developing targeted plasma protein supplementation (i.e., "replenishment") therapies for patients with heme toxicity due to HPX depletion.

KW - Erythrophagocytosis

KW - Haptoglobin

KW - Heme

KW - Hemolysis

KW - Hemolytic index

KW - Hemopexin

KW - Iron

KW - Plasma protein therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84940029623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940029623&partnerID=8YFLogxK

U2 - 10.3389/fphys.2015.00187

DO - 10.3389/fphys.2015.00187

M3 - Review article

C2 - 26175690

AN - SCOPUS:84940029623

VL - 6

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

IS - JUN

M1 - 187

ER -